Celldex Therapeutics shares are trading lower after the company reported that the Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis did not meet its primary endpoint. Also, Canaccord Genuity lowered its price target on the stock from $62 to $60.

Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $46

Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $40 to $46.

Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $53

Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $48 to $53.

Celldex Therapeutics Q2 EPS $(0.94) Beats $(1.07) Estimate, Sales $22.000K Miss $954.444K Estimate

Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.07) by 12.15 percent. This is a 10.59 percent decrease over losses of $(0.85) per share

Wells Fargo Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72